Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022

Detalhes bibliográficos
Autor(a) principal: Prates, Pedro Emílio Gomes
Data de Publicação: 2024
Outros Autores: Alonso, Jonas Bodini, Carvalho, Emília Campos de, Arcêncio, Ricardo Alexandre, Zamarioli, Cristina Mara
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/4473
Resumo: Introduction: The time taken for screening, detection and initiation of treatment is a determining factor for therapeutic management in oncology. The availability of reliable data guides decisions for public policies and evaluates compliance with these policies. Objective: To analyze the survival and outcomes of pediatric patients with leukemia and lymphoma from 2000 to 2022. Method: Epidemiological, descriptive study, with data extracted from Fundação Oncocentro do Estado de São Paulo, according to the International Classification of Childhood Cancer (ICCC). The time elapsed between the first consultation and diagnosis was evaluated, between diagnosis and the start of oncological treatment, and the survival of these patients, calculated according to the Peto-Peto test. Results: 12,030 cases were analyzed, 6,994 in males and 7,292 with leukemia. The probability of the time between consultation and diagnosis exceeds 30 days was 49.29% for leukemias and 76.31 for lymphomas, a significant result for treatment and relapses (p < 0.001) but not in relation to sex; the time between diagnosis and treatment exceeding 60 days was 38.04% for leukemias and 71.97% for lymphomas. Not undergoing treatment was significant (p < 0.001) while waiting for diagnosis after consultation for patients with leukemia and lymphomas, except surgery, chemotherapy and radiotherapy combined. Conclusion: Despite the advances, a considerable percentage of patients wait longer than expected for diagnosis and initiation of treatment, impacting their survival rates.
id INCA-1_bb7f57ed75820571ad1fdcbda4f68965
oai_identifier_str oai:rbc.inca.gov.br:article/4473
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022Análisis de Supervivencia en Pacientes Pediátricos con Leucemias y Linfomas en el Contexto Oncológico: Estudio Epidemiológico en el Estado de São Paulo, Brasil, 2000-2022Análise de Sobrevivência em Pacientes Pediátricos com Leucemias e Linfomas no Contexto Oncológico: Estudo Epidemiológico no Estado de São Paulo, Brasil, 2000-2022Análise de SobrevidaDiagnóstico LeucemiaDiagnóstico LinfomaTempo para o TratamentoSurvival AnalysisDiagnosis LeukemiaDiagnosis LymphomaAnálisis de SupervivenciaDiagnóstico LeucemiaDiagnóstico LinfomaTempo para o TratamentoIntroduction: The time taken for screening, detection and initiation of treatment is a determining factor for therapeutic management in oncology. The availability of reliable data guides decisions for public policies and evaluates compliance with these policies. Objective: To analyze the survival and outcomes of pediatric patients with leukemia and lymphoma from 2000 to 2022. Method: Epidemiological, descriptive study, with data extracted from Fundação Oncocentro do Estado de São Paulo, according to the International Classification of Childhood Cancer (ICCC). The time elapsed between the first consultation and diagnosis was evaluated, between diagnosis and the start of oncological treatment, and the survival of these patients, calculated according to the Peto-Peto test. Results: 12,030 cases were analyzed, 6,994 in males and 7,292 with leukemia. The probability of the time between consultation and diagnosis exceeds 30 days was 49.29% for leukemias and 76.31 for lymphomas, a significant result for treatment and relapses (p < 0.001) but not in relation to sex; the time between diagnosis and treatment exceeding 60 days was 38.04% for leukemias and 71.97% for lymphomas. Not undergoing treatment was significant (p < 0.001) while waiting for diagnosis after consultation for patients with leukemia and lymphomas, except surgery, chemotherapy and radiotherapy combined. Conclusion: Despite the advances, a considerable percentage of patients wait longer than expected for diagnosis and initiation of treatment, impacting their survival rates.Introducción: El tiempo necesario para el screening, detección e inicio del tratamiento es un factor determinante para el manejo terapéutico en oncología. La disponibilidad de datos confiables orienta las decisiones de políticas públicas y evalúa el cumplimiento de estas políticas. Objetivo: Analizar la supervivencia y desenlaces de pacientes pediátricos con leucemia y linfoma en el período de 2000 a 2022. Método: Estudio epidemiológico, descriptivo, con datos extraídos de la Fundación Oncocentro del estado de São Paulo, según la Clasificación Internacional del Cáncer Infantil. Se evaluó el tiempo transcurrido entre la primera consulta y el diagnóstico; entre el diagnóstico y el inicio del tratamiento oncológico, y la supervivencia de estos pacientes, calculada según la prueba de Peto-Peto. Resultados: Se analizaron 12 030 casos, con una prevalencia masculina de 6994; 7292 correspondieron a leucemia. La probabilidad de que el tiempo entre consulta y diagnóstico sea mayor a 30 días fue del 49,29% para leucemias y del 76,31 para linfomas, significativa para tratamiento y recaídas (p < 0,001) y no para sexo; para el tiempo entre diagnóstico y tratamiento, superior a 60 días, fue del 38,04% para las leucemias y del 71,97% para los linfomas. No recibir tratamiento fue significativo (p < 0,001) en la espera entre la consulta y el diagnóstico en pacientes con leucemia; lo mismo para los linfomas, excepto la combinación de cirugía, quimioterapia y radioterapia. Conclusión: A pesar de los avances logrados, un porcentaje considerable de pacientes espera un tiempo más de lo esperado para el diagnóstico y el inicio del tratamiento, impactando en las tasas de supervivencia de estos pacientes.Introdução: O tempo no rastreio, detecção e início do tratamento é fator determinante para o manejo terapêutico em oncologia. A disponibilidade de dados confiáveis orienta decisões para políticas públicas e avalia o cumprimento dessas políticas. Objetivo: Analisar a sobrevivência e desfechos de pacientes pediátricos com leucemias e linfomas de 2000 a 2022. Método: Estudo epidemiológico, descritivo, com dados extraídos da Fundação Oncocentro do Estado de São Paulo, segundo a Classificação Internacional de Câncer na Infância. Avaliou-se o tempo decorrido entre a primeira consulta e o diagnóstico; entre o diagnóstico e o início do tratamento oncológico; e a sobrevivência desses pacientes, calculada conforme o teste Peto-Peto. Resultados: Foram analisados 12.030 casos, com prevalência no sexo masculino 6.994; 7.292 corresponderam às leucemias. A probabilidade de o tempo entre a consulta e o diagnóstico ter sido superior a 30 dias foi de 49,29% para as leucemias e de 76,31 para os linfomas, significativo para o tratamento e recidivas (p < 0,001) e não por sexo; o tempo entre o diagnóstico e tratamento, superior a 60 dias, foi de 38,04% para as leucemias e de 71,97% para os linfomas. Não realizar tratamento foi significante (p< 0,001) na espera entre a consulta e o diagnóstico para os pacientes com leucemias; o mesmo para os linfomas, exceto para a combinação de cirurgia, quimioterapia e radioterapia. Conclusão: À despeito dos avanços obtidos, uma porcentagem considerável de pacientes aguarda um tempo maior do que o esperado para o diagnóstico e o início do tratamento, repercutindo nas taxas de sobrevivência desses pacientes.INCA2024-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/447310.32635/2176-9745.RBC.2024v70n1.4473Revista Brasileira de Cancerologia; Vol. 70 No. 1 (2024): Jan./Feb./Mar.; e-084473Revista Brasileira de Cancerologia; Vol. 70 Núm. 1 (2024): ene./feb./mar.; e-084473Revista Brasileira de Cancerologia; v. 70 n. 1 (2024): jan./fev./mar.; e-0844732176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAenghttps://rbc.inca.gov.br/index.php/revista/article/view/4473/3365Copyright (c) 2024 Revista Brasileira de Cancerologiahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPrates, Pedro Emílio GomesAlonso, Jonas BodiniCarvalho, Emília Campos deArcêncio, Ricardo AlexandreZamarioli, Cristina Mara2024-03-27T17:34:02Zoai:rbc.inca.gov.br:article/4473Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2024-03-27T17:34:02Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
Análisis de Supervivencia en Pacientes Pediátricos con Leucemias y Linfomas en el Contexto Oncológico: Estudio Epidemiológico en el Estado de São Paulo, Brasil, 2000-2022
Análise de Sobrevivência em Pacientes Pediátricos com Leucemias e Linfomas no Contexto Oncológico: Estudo Epidemiológico no Estado de São Paulo, Brasil, 2000-2022
title Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
spellingShingle Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
Prates, Pedro Emílio Gomes
Análise de Sobrevida
Diagnóstico Leucemia
Diagnóstico Linfoma
Tempo para o Tratamento
Survival Analysis
Diagnosis Leukemia
Diagnosis Lymphoma
Análisis de Supervivencia
Diagnóstico Leucemia
Diagnóstico Linfoma
Tempo para o Tratamento
title_short Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
title_full Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
title_fullStr Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
title_full_unstemmed Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
title_sort Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022
author Prates, Pedro Emílio Gomes
author_facet Prates, Pedro Emílio Gomes
Alonso, Jonas Bodini
Carvalho, Emília Campos de
Arcêncio, Ricardo Alexandre
Zamarioli, Cristina Mara
author_role author
author2 Alonso, Jonas Bodini
Carvalho, Emília Campos de
Arcêncio, Ricardo Alexandre
Zamarioli, Cristina Mara
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Prates, Pedro Emílio Gomes
Alonso, Jonas Bodini
Carvalho, Emília Campos de
Arcêncio, Ricardo Alexandre
Zamarioli, Cristina Mara
dc.subject.por.fl_str_mv Análise de Sobrevida
Diagnóstico Leucemia
Diagnóstico Linfoma
Tempo para o Tratamento
Survival Analysis
Diagnosis Leukemia
Diagnosis Lymphoma
Análisis de Supervivencia
Diagnóstico Leucemia
Diagnóstico Linfoma
Tempo para o Tratamento
topic Análise de Sobrevida
Diagnóstico Leucemia
Diagnóstico Linfoma
Tempo para o Tratamento
Survival Analysis
Diagnosis Leukemia
Diagnosis Lymphoma
Análisis de Supervivencia
Diagnóstico Leucemia
Diagnóstico Linfoma
Tempo para o Tratamento
description Introduction: The time taken for screening, detection and initiation of treatment is a determining factor for therapeutic management in oncology. The availability of reliable data guides decisions for public policies and evaluates compliance with these policies. Objective: To analyze the survival and outcomes of pediatric patients with leukemia and lymphoma from 2000 to 2022. Method: Epidemiological, descriptive study, with data extracted from Fundação Oncocentro do Estado de São Paulo, according to the International Classification of Childhood Cancer (ICCC). The time elapsed between the first consultation and diagnosis was evaluated, between diagnosis and the start of oncological treatment, and the survival of these patients, calculated according to the Peto-Peto test. Results: 12,030 cases were analyzed, 6,994 in males and 7,292 with leukemia. The probability of the time between consultation and diagnosis exceeds 30 days was 49.29% for leukemias and 76.31 for lymphomas, a significant result for treatment and relapses (p < 0.001) but not in relation to sex; the time between diagnosis and treatment exceeding 60 days was 38.04% for leukemias and 71.97% for lymphomas. Not undergoing treatment was significant (p < 0.001) while waiting for diagnosis after consultation for patients with leukemia and lymphomas, except surgery, chemotherapy and radiotherapy combined. Conclusion: Despite the advances, a considerable percentage of patients wait longer than expected for diagnosis and initiation of treatment, impacting their survival rates.
publishDate 2024
dc.date.none.fl_str_mv 2024-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/4473
10.32635/2176-9745.RBC.2024v70n1.4473
url https://rbc.inca.gov.br/index.php/revista/article/view/4473
identifier_str_mv 10.32635/2176-9745.RBC.2024v70n1.4473
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/4473/3365
dc.rights.driver.fl_str_mv Copyright (c) 2024 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2024 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 70 No. 1 (2024): Jan./Feb./Mar.; e-084473
Revista Brasileira de Cancerologia; Vol. 70 Núm. 1 (2024): ene./feb./mar.; e-084473
Revista Brasileira de Cancerologia; v. 70 n. 1 (2024): jan./fev./mar.; e-084473
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042242000519168

Registros relacionados